Advertisement

Ex Vivo Manipulation of Peripheral Blood CD34+ Cells

  • W. Brugger
  • S. Scheding
  • H.-J. Bühring
  • W. Vogel
  • B. Ziegler
  • P. Brossart
  • G. Stuhler
  • L. Kanz
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

The success of autologous peripheral blood progenitor cell (PBPC) transplantation is challenged by relapse of malignant disease which might — at least in part — be mediated by graft contaminating tumor cells. Although the clinical role of tumor cell depletion still remains to be demonstrated in prospective, randomized trials, multiple purging strategies are currently pursued in the context of autologous stem cell transplantation. This report is discussing ex vivo manipulations of PBPC transplants with respect to purging of tumor cells, including the positive selection of CD34+ cells with or without negative depletion as well as ex vivo expansion techniques. In addition, adoptive immunotherapy strategies using ex vivo generated autologous dendritic cells for the treatment of minimal residual disease after stem cell transplantation will be discussed.

Keywords

Minimal Residual Disease Stem Cell Factor Autologous Bone Marrow Peripheral Blood CD34 Genitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Anderson WF, Ihle N (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341: 85–86PubMedCrossRefGoogle Scholar
  2. 2.
    Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK (1994) Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84: 380–383PubMedGoogle Scholar
  3. 3.
    Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF et al. (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogeneous leukemia ( CML) contribute to relapse after autologous bone marrow in CML. Blood 83: 3068–3076PubMedGoogle Scholar
  4. 4.
    Gribben JG, Freedman AS, Neuberg D, Denis SD, Roy DC, Bloake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler AM (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma. N Engl J Med 325: 1525PubMedCrossRefGoogle Scholar
  5. 5.
    Berardi AC, Wang A, Levine JD, Lopez P, Scadden DT (1995) Functional isolation and characterization of human hematopoietic stem cells. Science 267: 104–108PubMedCrossRefGoogle Scholar
  6. 6.
    Lee YY, Kim ES, Seol JG, Kim BK, Binderup L, Elstner E, Park DJ, Koeffler HP (1996) A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 88: 2201–2209Google Scholar
  7. 7.
    Lee YY, Kim ES, Seol JG, Kim BK, Binderup L, Elstner E, Park DJ, Koeffler HP (1996) Effect of a vitamin D3 analog, EB1089, on hematopoietic stem cells from normal and myeloid leukemic blasts. Leukemia 10: 1751–1757PubMedGoogle Scholar
  8. 8.
    Biihring HJ, Dill P, Kanz L, Brugger W (1996) Differential expression of receptor tyrosine kinases c-kit, c-fms, FLT-3, PDGF-RA/RB, HER2, HER3, and the mucin molecule MUC-1 on primary acute leukemic blasts. Blood 88: 366aGoogle Scholar
  9. 9.
    Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D et al. (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605–2610PubMedGoogle Scholar
  10. 10.
    Shpall E J, Jones RB (1994) Release of tumor cells from bone marrow. Blood 83: 623–625PubMedGoogle Scholar
  11. 11.
    Brugger W, Bross KJ, Glatt M, Weber F, Mertels-mann R, Kanz (1994) Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636–640Google Scholar
  12. 12.
    Sharp JG, Joshi SS, Armitage JO, Bierman P, Coc-cia PF, Harrington DS, Kessinger A, Crouse DA, Mann SL, Weisenburger DD (1992) Significance of detection of occult non-Hodgkin’s lymphoma in histologically uninvolvend bone marrow by a culture techniques. Blood 79: 1074–1080PubMedGoogle Scholar
  13. 13.
    Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giu-dice V, Nannetti A, Martinelli G, Cavo M, Ama-bile M, Mangianti S, Fogli M, Conte R, Tura S (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 87: 1625–1634PubMedGoogle Scholar
  14. 14.
    Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH et al. (1995) Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86: 390–397PubMedGoogle Scholar
  15. 15.
    Gorin NC, Lopez M, Laporte JP, Quittet P, Lesage S, Lemoine F, Berenson RJ, Isnard F, Grande M, Stachowiak J, Oabopin M, Fouilard L, Morel P, Jouet JP, Noel-Walter MP, Detourmignies L, Aoudjhane M, Bauters F, Najman A, Douay L (1995) Preparation and successful engraftment of purified CD34+ bone marrow progentior cells in patients with non-Hodgkin’s lymphoma. Blood 85: 1647–1654PubMedGoogle Scholar
  16. 16.
    Berenson RJ, Shpall EJ, Franklin WA et al. (1995) Transplantation of CD34 positive marrow and/or peripheral blood progenitor cells into breast cancer patients following high-dose chemotherapy. Bone Marrow Transplant 15 (Suppl2): S32Google Scholar
  17. 17.
    Dreger P, von Neuhoff N, Suttorp M, Loffler H, Schmitz N (1995) Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immu-nomagnetic beads. Bone Marrow Transplan 16: 627–629Google Scholar
  18. 18.
    Dreger P, Viehmann K, Steinmann J, Eckstein V, Muller-Ruchholtz W, Loffler H, Schmitz N (1995) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAM- PATH-I.Exp Hematol 23: 147–154PubMedGoogle Scholar
  19. 19.
    Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L (1993) Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin- 1BBB, interleukin-6, interleukin-3, interferon-gamma, and erythropoietin. Blood 81: 2579–2584PubMedGoogle Scholar
  20. 20.
    Henschler R, Brugger W, Luft T, Frey T, Mertels-mann R, Kanz L (1994) Maintenance of transplantation potential in ex-vivo expanded CD34+-selected human peripheral blood progenitor cells. Blood 84: 2898–2903PubMedGoogle Scholar
  21. 21.
    Shapiro F, Yao TJ, Rapti G, Reich L, Norton L, Moore MAS (1994) Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood 84: 3567PubMedGoogle Scholar
  22. 22.
    Haylock DN, To LB, Dose TL, Juttner CA, Simmons PJ (1992) Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 80: 1405PubMedGoogle Scholar
  23. 23.
    Emerson SG (1996) Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 87: 3082–3088PubMedGoogle Scholar
  24. 24.
    Kessinger A (1995) Circulating stem cells - waxing hematopoietic. N Engl J Med 333: 315PubMedCrossRefGoogle Scholar
  25. 25.
    Brugger W, Heimfeld S, Berenson RJ, Mertels-mann R, Kanz (1995) Reconstitution of hemato-poiesis after high-dose chemotherapy by autologous progenitor calls generated ex vivo. N Engl J Med 333: 283–287PubMedCrossRefGoogle Scholar
  26. 26.
    Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ (1996) Self-renewal of primitive human hematopoietic cells (long-term culture initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Science USA 93: 1470CrossRefGoogle Scholar
  27. 27.
    Peters SO, Kittler ELW, Ramshaw HS, Quesen-berry PJ (1996) Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL- 11, and stem cell factor leads to impaired en-graftment in irradiated hosts. Blood 87: 30PubMedGoogle Scholar
  28. 28.
    Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M (1996) Interleukin-3 or interleukin-1 abrogates the reconstitution ability of hematopoietic stem cells. Proc Natl Acad Sci USA 93: 4040PubMedCrossRefGoogle Scholar
  29. 29.
    Spangrude GJ, Brooks DM, Tumas DB (1995) Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell pheno-type but not function. Blood 85: 1006–1016PubMedGoogle Scholar
  30. 30.
    Muench MO, Firpo MT, Moore MA (1993) Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 81: 3463PubMedGoogle Scholar
  31. 31.
    Yonemura Y, Ku H, Lyman SD, Ogawa M (1997) In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between FLT3/FLK-2 ligand and KIT-ligand. Blood 89: 1915–1921PubMedGoogle Scholar
  32. 32.
    Vogel W, Behringer D, Scheding S, Kanz L, Brugger W (1996) Ex vivo expansion of CD34+ peripheral blood progenitor cells: Implications for the expansion of contaminating tumor cells. Blood 88: 2707–2713PubMedGoogle Scholar
  33. 33.
    Brugger W, Scheding S, Vogel W, Kanz L (1996) Purging of peripheral blood progenitor cells. Ann Oncol 7: 11–13 (suppl)Google Scholar
  34. 34.
    Herbst B, Kohler G, Mackensen A, Veelken H, Kulmburg P, Rosenthal FM, Schaefer HE, Mer-telsmann R, Fisch P, Lindemann A (1996) In vitro differentiation of CD34+ hematopoietic progenitor cells toward distinct dendritic cell subsets of the birbeck granule and MUC-positive Langerhans cell and the interdigitating dendritic cell type. Blood 88: 2541–2548PubMedGoogle Scholar
  35. 35.
    Fisch P, Köhler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L (1996) Generation of antigen-presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients. Eur J Immunol 26: 595–600PubMedCrossRefGoogle Scholar
  36. 36.
    Peters HJ, Gieseler R, Thiele B, Steinbach F (1996) Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol Today 17: 273–278PubMedCrossRefGoogle Scholar
  37. 37.
    Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, MrKenna H J (1996) Dramatic increase in the numbers of functionally mature dendritic cells in FLT3 Ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184: 1953–1962PubMedCrossRefGoogle Scholar
  38. 38.
    Schading S, Gruber I, Bühring H J, Ziegler B, Kaiserling E, Kanz L, Brugger W (1996) F LT-3 ligand promotes the ex-vivo generation of CDla+ cells from CD34+ peripheral blood progenitor cells. Exp Hematol 24: 1044 [abstract]Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • W. Brugger
    • 1
  • S. Scheding
    • 1
  • H.-J. Bühring
    • 1
  • W. Vogel
    • 1
  • B. Ziegler
    • 1
  • P. Brossart
    • 1
  • G. Stuhler
    • 1
  • L. Kanz
    • 1
  1. 1.Department of HematologyOncology and Immunology University of TübingenTübingenGermany

Personalised recommendations